Abstract
Liver cirrhosis is a progressive and irreversible end-stage condition of chronic liver disease, contributing to more than 2 million deaths globally each year. Among its numerous etiologies, chronic viral hepatitis, particularly hepatitis B (HBV) and hepatitis C (HCV), remain the most significant, preventable, and treatable causes. This review critically explores the epidemiology, pathogenesis, clinical classification, complications, and therapeutic approaches in managing hepatitis-induced liver cirrhosis. Effective antiviral regimens, including nucleos(t)ide analogues like Tenofovir and Entecavir for HBV, and direct-acting antivirals (DAAs) for HCV, have shown remarkable success in reducing viral load, delaying disease progression, and improving survival. Nonetheless, the global challenge lies in ensuring early detection, universal access, and adherence to therapy. Moreover, the emergence of cirrhotic complications—ascites, hepatic encephalopathy, portal hypertension, and renal dysfunction—demands integrated clinical management and continuous monitoring. In recent years, there has been a resurgence of interest in hepatoprotective agents, especially those derived from natural sources like flavonoids, silymarin, glycyrrhizin, and curcumin. These compounds exhibit potent antioxidant, anti-inflammatory, and antifibrotic actions, offering adjunctive support in liver protection and regeneration. Their safety, affordability, and bioactivity make them valuable in both prevention and supportive care in chronic liver conditions. Furthermore, emerging tools such as AI-driven diagnostics, non-invasive imaging, precision medicine, and biomarker-guided monitoring are shaping a more individualized approach to liver care. However, the full potential of these advancements will only be realized through equitable healthcare access, population-based screening programs, lifestyle modification, and policy-level reforms.
Keywords
Liver Cirrhosis, Management, Etiology, Complications, Emerging Hepatoprotective Agents, Novel Treatment Modalities
Introduction
Liver is a highly integrative organ involved in the metabolism, detoxification, production of bile salts and acids, and in homeostasis. Hepatocytes are the functional and structural unit of the liver, comprising 80% of its mass. The non-hepatocyte auxiliary cells are Kupfer cells, stellate cells, sinusoidal endothelial cells and cholangiocytes, which play an important role in the liver function. [1] Over 2 million deaths are accounted every year due to the liver disease, contributed to the 4% of the total death in the world. Alarmingly, the ratio of death in male is more than female, which is two-thirds. According to these statistics, the liver disease becomes 11th most common cause of death globally. [2] Liver disease can be acute or chronic depending upon the cause and condition of the liver. The common cause for acute liver conditions is viral infection, drug-induced liver injury, toxin exposure, and fatty liver. On the other hand, the chronic diseases are caused by viral hepatitis (B and C), alcoholic liver disease, non-alcoholic fatty liver disease (NAFLD) globally. Liver cirrhosis is characterized by irreversible damaging the liver tissue and Sequential replacement with the scar tissue results in reduced liver function. Liver cirrhosis is marked as the end stage of the liver disease. It starts with the inflammation of the liver (Hepatitis) progressing to liver fibrosis, ultimately ends with liver cirrhosis. This disease contributes to high mortality rate and high morbidity rate across the world. [3] Largely, the death rates are due to liver cirrhosis and primary liver cancer, particularly hepatocellular carcinoma. To a lesser extent, the acute hepatitis also plays a role in liver-related mortality. The various causes of liver cirrhosis include Hepatitis B and C, Alcoholic related and NAFLD. Thus, this review aims to consolidate epidemiology and characteristics of liver disease, focusing on hepatitis-induced liver cirrhosis, along with current findings on anti-viral medications and hepatoprotective strategies in the management of hepatitis-induced liver cirrhosis. We also aim to highlight the recent advances, existing challenges, and potential future research directions for hepatitis-induced liver cirrhosis.
Etiology and Risk Factors of Liver Cirrhosis
Liver cirrhosis is an irreversible condition resulting from the long-term liver damage characterized by chronic and progressive liver disease. Cirrhosis is caused by a variety of factors contributing to its development that leads to fibrosis, scarring, and liver failure. Multiple ideological factors cause the liver to become damaged more quickly. It includes viral infections, metabolic disorders, autoimmune disorders, alcohol abuse, and biliary conditions. [4] These diverse etiologies are summarized in Table 1. However, this review specifically focuses on the cirrhosis caused by hepatitis, given their significant global burden and clinical relevance.
Table 1: Aetiology of Cirrhosis[5]
|
Category
|
Causes
|
|
Viral
|
Hepatitis B*
Hepatitis C*
Hepatitis D (usually superimposed on a Hepatitis B infection)
|
|
Alcohol-related
|
Alcohol-related liver disease*
|
|
Metabolic and Genetic
|
Non-alcoholic fatty liver disease*
Haemochromatosis
Wilson’s disease
α1-antitrypsin deficiency
Cystic fibrosis
Lysosomal acid lipase deficiency
Progressive familial intrahepatic cholestasis
Tyrosinaemia type 1
Type IV glycogen storage disease
|
|
Autoimmune
|
Autoimmune hepatitis
Primary biliary cholangitis
Primary sclerosing cholangitis
|
|
Biliary
|
Biliary atresia
Biliary strictures
|
|
Vascular
|
Budd–Chiari syndrome
Veno-occlusive disease
Fontan-associated liver disease
Cardiac cirrhosis
|
|
Drug-related (Long-term use) †
|
Methotrexate
Amiodarone
Methyldopa
Vitamin A
|
|
Cryptogenic
|
Cause uncertain
|
* Common causes of cirrhosis.
† Long-term use not clearly defined; risk varies with obesity, alcohol intake, and other factors.
Reference
- Sah AK, Afzal M, Elshaikh RH, Abbas AM, Shalabi MG, Prabhakar PK, Babker AMA, Khalimova FT, Sabrievna VA, Choudhary RK. Innovative Strategies in the Diagnosis and Treatment of Liver Cirrhosis and Associated Syndromes. Life (Basel). 2025 May 13;15(5):779. doi:10.3390/life15050779
- Devarbhavi H, Asrani SK, Arab JP, Nartey YA, Pose E, Kamath PS. Global burden of liver disease: 2023 update. J Hepatol. 2023 Aug;79(2):516–537. doi: 10.1016/j.jhep.2023.03.017.
- Wong MCS, Huang JLW, George J, Huang J, Leung C, Eslam M, Chan HLY, Ng SC. The changing epidemiology of liver diseases in the Asia-Pacific region. Nat Rev Gastroenterol Hepatol. 2019;16(1):57–73. doi:10.1038/s41575-018-0066-1
- Kamath PS, Shah V. Overview of cirrhosis. In: Qayed E, Shahnavaz N, editors. Sleisenger and Fordtran’s gastrointestinal and liver disease: review and assessment. 11th ed. Philadelphia (PA): Elsevier; 2020. p. 1164–71.
- Ginès P, Krag A, Abraldes JG, Solà E, Fabrellas N, Kamath PS. Liver cirrhosis. Lancet. 2021 Oct 9;398(10308):1359–1376. doi:10.1016/S0140-6736(21)01374-X
- Shashidhar KN, Nallagangula KS. Pros and cons of existing biomarkers for cirrhosis of liver. Sri DevarajUrs Medical College Publications. May 2019.
- Francis DP, Favero MS, Maynard JE. Transmission of hepatitis B virus. Semin Liver Dis. 1981;1(1):27–32. PMID: 7051293. doi:10.1055/s-2008-1063927.
- World Health Organization. Global hepatitis report 2017. [Internet]. 2017 [cited 2021 Jan 19]. Available from: https://www.who.int/publications/i/item/global-hepatitis-report-2017
- Prasidthrathsint K, Stapleton JT. Laboratory diagnosis and monitoring of viral hepatitis. Gastroenterol Clin North Am. 2019;48(2):259–79. PMID: 31046974. doi:10.1016/j.gtc.2019.02.007.
- Tun W, Vu L, Adebajo SB, Abiodun L, Sheehy M, Karlyn A, Njab J, Ahonsi B, Issa BK, Idogho O. Population-based prevalence of hepatitis B and C virus, HIV, syphilis, gonorrhoea and chlamydia in male injection drug users in Lagos, Nigeria. Int J STD AIDS. 2013 Aug;24(8):619-25. [PubMed: 23970571]
- Ahmed Z, Shetty A, Victor DW, Kodali S. Viral hepatitis: A narrative review of hepatitis A–E. World J Meta-Anal. 2022;10(3):99–121. doi:10.13105/wjma. v10.i3.99.
- Castaneda D, Gonzalez AJ, Alomari M, Tandon K, Zervos XB. From hepatitis A to E: A critical review of viral hepatitis. World J Gastroenterol. 2021 Apr 28;27(16):1691–1715. doi:10.3748/wjg. v27.i16.1691. PMID: 33977213.
- Zaki MYW, Fathi AM, Samir S, Eldafashi N, William KY, Nazmy MH, Fathy M, Gill US, Shetty S. Innate and adaptive immunopathogeneses in viral hepatitis; crucial determinants of hepatocellular carcinoma. Cancers (Basel). 2022;14(5):1255. doi:10.3390/cancers14051255.
- D’Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: A systematic review of 118 studies. J Hepatol. 2006;44(1):217–31. doi: 10.1016/j.jhep.2005.10.013
- Tsochatzis EA, Papatheodoridis GV, Manesis EK, Kafiri G, Tiniakos DG, Archimandritis AJ. Metabolic syndrome is associated with severe fibrosis in chronic viral hepatitis and non-alcoholic steatohepatitis. Aliment PharmacolTher. 2008;27(1):80–89. doi:10.1111/j.1365-2036.2007. 03546.x
- García-Pagán JC, Gracia-Sancho J, Bosch J. Functional aspects on the pathophysiology of portal hypertension in cirrhosis. J Hepatol. 2012;57(2):458–61.4
- Jagdish RK, Roy A, Kumar K, Premkumar M, Sharma M, Rao PN, Reddy DN, Kulkarni AV. Pathophysiology and management of liver cirrhosis: from portal hypertension to acute?on?chronic liver failure. Front Med (Lausanne). 2023; 10:1060073. doi:10.3389/fmed.2023.1060073
- Attali P, Ink O, Pelletier G, Vernier C, Jean F, Moulton L, Etienne JP. Dupuytren’s contracture, alcohol consumption, and chronic liver disease. Arch Intern Med. 1987 Jun;147(6):1065–1067. doi:10.1001/archinte.1987.00370060061012
- Udell JA, Wang CS, Tinmouth J, FitzGerald JM, Ayas NT, Simel DL. Does this patient with liver disease have cirrhosis? JAMA. 2012;307(8):832–42.
- Thiele M, Madsen BS, Hansen JF, Detlefsen S, Antonsen S, Krag A. Accuracy of the enhanced liver fibrosis test vs FibroTest, elastography, and indirect markers in detection of advanced fibrosis in patients with alcoholic liver disease. Gastroenterology. 2018;154(5):1369–79.
- Tsochatzis EA, Bosch J, Burroughs AK. Liver cirrhosis. Lancet. 2014 Jan 28;383(9930):1749–61. doi:10.1016/S0140-6736(14)60121-5
- Fadlallah H, El Masri D, Bahmad HF, Abou?Kheir W, El Masri J. Update on the complications and management of liver cirrhosis. Med Sci (Basel). 2025;13(1):13. doi:10.3390/medsci13010013
- Huang DQ, Hoang JK, Kamal R, Tsai PC, Toyoda H, Yeh ML. Antiviral therapy utilization and 10?year outcomes in resected hepatitis B virus– and hepatitis C virus–related hepatocellular carcinoma. J Clin Oncol. 2024;42(7):790–799.
- Huang DQ, Tran A, Yeh ML, Yasuda S, Tsai PC, Huang CF, et al. Antiviral therapy substantially reduces HCC risk in patients with chronic hepatitis B infection in the indeterminate phase. Hepatology. 2023;78(5):1558–1568.
- Chow N, Wong D, Lai CL, Mak LY, Fung J, Ma HT, et al. Effect of antiviral treatment on hepatitis B virus integration and hepatocyte clonal expansion. Clin Infect Dis. 2023;76(3):e801–e809.
- Chien RN, Liaw YF. Current trend in antiviral therapy for chronic hepatitis B. Viruses. 2022;14(3):434.
- Huang ZH, Lu GY, Qiu LX, Zhong GH, Huang Y, Yao XM, Liu XH, et al. Risk of hepatocellular carcinoma in antiviral treatment?naïve chronic hepatitis B patients treated with entecavir or tenofovir disoproxil fumarate: a network meta?analysis. BMC Cancer. 2022; 22:287.
- Chan HLY, Fung S, Seto WK, Chuang WL, Chen CY, Kim HJ, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg?positive chronic hepatitis B virus infection: a randomised, double?blind, phase 3, non?inferiority trial. Lancet Gastroenterol Hepatol. 2016;1(3):185–195.
- Kim WR, Loomba R, Berg T, Aguilar Schall RE, Yee LJ, Dinh PV, et al. Impact of long?term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis B. Cancer. 2015;121(20):3631–3638.
- Coppola N, Alessio L, De Pascalis S, Macera M, Di Caprio G, Messina V, et al. Effectiveness of test?and?treat model with direct?acting antiviral for hepatitis C virus infection in migrants: a prospective interventional study in Italy. Infect Dis Poverty. 2024;13(1):39. doi:10.1186/s40249-024-01200-9
- Liu CH, Kao JH. Acute hepatitis C virus infection: clinical update and remaining challenges. Clin Mol Hepatol. 2023;29(3):623–636. doi:10.3350/cmh.2023.0102
- Dietz C, Maasoumy B. Direct?acting antiviral agents for hepatitis C virus infection—From drug discovery to successful implementation in clinical practice. Viruses. 2022;14(6):1325. doi:10.3390/v14061325
- Solomon SS, Wagner?Cardoso S, Smeaton L, Sowah LA, Wimbish C, Robbins G, et al. A minimal monitoring approach for the treatment of hepatitis C virus infection (ACTG A5360 [MINMON]): a phase 4, open?label, single?arm trial. Lancet Gastroenterol Hepatol. 2022;7(4):307–317. doi:10.1016/S2468-1253(21)00397-6
- Parlati L, Hollande C, Pol S. Treatment of hepatitis C virus infection. Clin Res Hepatol Gastroenterol. 2021;45(1):101574. doi: 10.1016/j.clinre.2020.11.008
- Mazzaro C, Quartuccio L, Adinolfi LE, Roccatello D, Pozzato G, Nevola R, et al. A review on extrahepatic manifestations of chronic hepatitis C virus infection and the impact of direct?acting antiviral therapy. Viruses. 2021;13(11):2249. doi:10.3390/v13112249
- Thiele M, Pose E, Juanola A, Mellinger J, Ginès P. Population screening for cirrhosis. Hepatology Communications. 2024 Aug 26;8(9):e0512. doi:10.1097/HC9.0000000000000512
- Lin B, Ma Y, Wu S. Multi-omics and artificial intelligence-guided data integration in chronic liver disease: prospects and challenges for precision medicine. OMICS. 2022 Aug;26(8):415–421. doi:10.1089/omi.2022.0079
- Zhou L, Li Y, Liang Q, Liu J, Liu Y. Combination therapy based on targeted nano drug co-delivery systems for liver fibrosis treatment: A review. J Drug Target. 2022;30(6):577–588.
- Gu L, Zhang F, Wu J, Zhuge Y. Nanotechnology in drug delivery for liver fibrosis. Front MolBiosci. 2022; 8:804396.
- Liu J, Liu J, Mu W, Ma Q, Zhai X, Jin B, et al. Delivery strategy to enhance the therapeutic efficacy of liver fibrosis via nanoparticle drug delivery systems. ACS Nano. 2024;18(32):20861-85.
- Peng W, Cheng S, Bao Z, Wang Y, Zhou W, Wang J, et al. Advances in the research of nanodrug delivery system for targeted treatment of liver fibrosis. Biomed Pharmacother. 2021; 137:111342.
- Singh S, Sharma N, Shukla S, Behl T, Gupta S, Anwer MK, et al. Understanding the potential role of nanotechnology in liver fibrosis: a paradigm in therapeutics. Molecules. 2023;28(6):2811.
- Putra R, Wardhani S, Santoso B, Permata I, Yusof ZB, Pratama A, et al. Evaluation of novel drug delivery systems for enhancing the therapeutic outcomes in hepatic disorders. Hepatic Disord Rev. 2023.
- Roy SD, Das S, Shil D, Dutta KN. Herbal hepatoprotective agents: a review. World J Pharm Res. 2012;1(2):87–99.
- Aghemo A, Alekseeva OP, Angelico F, Bakulin IG, Bakulina NV, Bordin D, Bueverov AO, Drapkina OM, Gillessen A, Kagarmanova EM, Korochanskaya NV, Kucheryavii UA, Lazebnik LB, Livzan MA, Maev IV, Martynov AI, Osipenko MF, Sas EI, Starodubova A, Uspensky YP, Vinnitskaya EV, Yakovenko EP, Yakovlev AA. Role of silymarin as antioxidant in clinical management of chronic liver diseases: a narrative review. Ann Med. 2022;54(1):1548–1560. doi:10.1080/07853890.2022.2069854.
- Wahab S, Annadurai S, Abullais SS, Das G, Ahmad W, Ahmad MF, Kandasamy G, Vasudevan R, Ali MS, Amir M. Glycyrrhiza glabra (Licorice): a comprehensive review on its phytochemistry, biological activities, clinical evidence and toxicology. Plants. 2021;10(12):2751. doi:10.3390/plants10122751
- Sun H, Liu T, Wang Z, Shen W, Yuan X, Xie J, Zhang Y. Role of curcumin in chronic liver diseases: a comprehensive review. Drug Des Devel Ther. 2025; 19:3395–3406. doi:10.2147/DDDT.S518547
- Anderson J. Mechanistic insights into the hepatoprotective role of andrographolide from Andrographis paniculata. [Internet]. Obafemi Awolowo University; Feb 2025 [cited 2025 Jul?10]. Available from: ResearchGate: Mechanistic Insights into the Hepatoprotective Role of Andrographolide
- Koperska A, Weso?ek A, Moszak M, Szuli?ska M. Berberine in non?alcoholic fatty liver disease—A review. Nutrients. 2022;14(17):3459. doi:10.3390/nu14173459
- Almeleebia TM, Alsayari A, Wahab S. Pharmacological and clinical efficacy of Picrorhizakurroa and its secondary metabolites: a comprehensive review. Molecules. 2022;27(23):8316. doi:10.3390/molecules27238316
- Wan Saidin WA, Jantan I, Abdul Wahab SM, Jalil J, Mohd Said M, Yusoff SD, Husain K. Pharmacological activities and mechanisms of action of hypophyllanthin: a review. Front Pharmacol. 2023; 13:1070557. doi:10.3389/fphar.2022.1070557
- Bakry SM, El?Shiekh RA, Hatem S, Mandour AA, El?Dessouki AM, Bishr A, Elosaily H, Mohamed AF, Elhussein SM. Therapeutic applications of ursolic acid: a comprehensive review and utilization of predictive tools. Future J Pharm Sci. 2025;11(1):1–38. doi:10.1186/s43094-025-00796-5
- Qin F, Chen Y, Wang F?F, Tang S?Q, Fang Y?L. Corydalis saxicola Bunting: a review of its traditional uses, phytochemistry, pharmacology, and clinical applications. Int J Mol Sci. 2023;24(2):1626. doi:10.3390/ijms24021626
- Huang CH, Wu VCC, Wang CL, Wu CL, Huang YT, Chang SH. Silymarin synergizes with antiviral therapy in hepatitis B virus–related liver cirrhosis: a propensity score matching multi?institutional study. Int J Mol Sci. 2024;25(6):3088. doi:10.3390/ijms25063088
- Peng D, Xing HY, Li C, Wang XF, Hou M, Li B, Chen JH. The clinical efficacy and adverse effects of entecavir plus thymosin α?1 combination therapy versus entecavir monotherapy in HBV?related cirrhosis: a systematic review and meta?analysis. BMC Gastroenterol. 2020;20(1):348. doi:10.1186/s12876-020-01477-8
- Curry MP, O’Leary JG, Bzowej N, et al. Sofosbuvir and velpatasvir with or without ribavirin in patients with decompensated cirrhosis. N Engl J Med. 2015;373(27):2618–2628. doi:10.1056/NEJMoa1512614
- Long LH, Xue CQ, Shi JF, Dong JN, Wang L. Efficacy of hepatoprotective agents with or without antiviral drugs on liver function and fibrosis in patients with hepatitis B: a meta?analysis. Hepat Mon. 2015;15(7):e29052. doi:10.5812/hepatmon.29052v2
- Wen T, Wang T, Zhu H, Cao Z, Liu F. Efficacy of hepatoprotective formula, entecavir, and continuous nursing in patients with hepatitis B cirrhosis. Altern Ther Health Med. 2024 Jul 19: e2024?AT10?567.
- Yu W, Ge CQ. Effects of BushenHuayu Decoction combined with entecavir on liver function and hepatic fibrosis in patients with compensated cirrhosis. Am J Transl Res. 2024;16(8):4163–4173. doi:10.62347/QDXJ3369.
Mohammed Fazan O.
Corresponding author
Department of Pharmaceutics, C. L. Baid Metha College of Pharmacy
Selvi G.
Co-author
Department of Pharmaceutics, C. L. Baid Metha College of Pharmacy
Anandha Krishnan
Co-author
Department of Pharmaceutics, C. L. Baid Metha College of Pharmacy
Mohammed Fazan O.*, Selvi G., Anandha Krishnan, Liver Cirrhosis and Its Management: A Comprehensive Review on Etiology, Complications, Emerging Hepatoprotective Agents and Novel Treatment Modalities, Int. J. Sci. R. Tech., 2025, 2 (8), 291-309. https://doi.org/10.5281/zenodo.16903653
10.5281/zenodo.16903653
